TARGETING PROGRAMMED CELL DEATH-1 (PD-1)
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Presentation
- By: HARVEY, R. Donald (Winship Cancer Institute of Emory University, Hematology/Medical Oncology, Avondale Estates, United States)
- Co-author(s): R. Donald Harvey
Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against a number of cancer types. The US FDA has approved pembrolizumab for the treatment of advanced melanoma and nivolumab for advanced melanoma and squamous cell non-small cell lung.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.